Analyst: US vaccine order secures future cash flow for Bavarian

BARDA has utilized a contract option concerning freeze-dried smallpox vaccines developed by Bavarian, something Sydbank analyst Søren Løntoft Hansen sees as a positive signal for the biotech firm.
Photo: Philip Davali/Ekstra Bladet, Philip Davali
Photo: Philip Davali/Ekstra Bladet, Philip Davali
by marketwire, translated by catherine brett

Bavarian Nordic has secured million-dollar incomes for the next few years, as the US Biomedical Advanced Research and Development Authority (BARDA) has utilized its contracted option on Bavarian’s freeze-dried smallpox vaccine, Jynneos.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading